Sunmax Biotechnology Co Ltd (4728) — Cash Flow-to-Debt Ratio
Sunmax Biotechnology Co Ltd (4728) has a Cash Flow-to-Debt Ratio of 0.35x as of September 2025, meaning its operating cash flow of NT$160.84 Million could theoretically repay 0% of its total liabilities (NT$454.35 Million) in one year. See Sunmax Biotechnology Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sunmax Biotechnology Co Ltd Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Sunmax Biotechnology Co Ltd across 10 annual periods. Also explore 4728 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sunmax Biotechnology Co Ltd (2015–2024)
Year-by-year debt coverage analysis for Sunmax Biotechnology Co Ltd. For market capitalisation and broader financial context, see 4728 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.18x | NT$397.37 Million | NT$337.82 Million | ▲ +1.6% |
| 2023 | 1.16x | NT$848.56 Million | NT$732.99 Million | ▲ +58.0% |
| 2022 | 0.73x | NT$342.97 Million | NT$468.00 Million | ▲ +38.7% |
| 2021 | 0.53x | NT$243.28 Million | NT$460.44 Million | ▼ -35.1% |
| 2020 | 0.81x | NT$386.97 Million | NT$475.27 Million | ▲ +22.6% |
| 2019 | 0.66x | NT$289.51 Million | NT$435.82 Million | ▼ -27.6% |
| 2018 | 0.92x | NT$100.83 Million | NT$109.88 Million | ▲ +118.2% |
| 2017 | 0.42x | NT$37.09 Million | NT$88.22 Million | ▲ +7.0% |
| 2016 | 0.39x | NT$16.58 Million | NT$42.20 Million | ▲ +176.3% |
| 2015 | -0.52x | NT$-22.84 Million | NT$44.33 Million | — |